Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene

Molecular Therapy

Volumn 10, Issue 3, 2004, Pages 574-584

  Budak Alpdogan, Tulin ^a   Alpdogan, Onder ^b   Banerjee, Debabrata ^a   Wang, Eunice ^b   Moore, Malcolm A S ^b   Bertino, Joseph R ^a,c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Chemotherapy; Drug resistance fusion gene; Gene therapy; Human lymphoma; NOD SCID mouse; Posttransplant

Indexed keywords

COMPLEMENTARY DNA; CYTARABINE; CYTIDINE DEAMINASE; DIHYDROFOLATE REDUCTASE; METHOTREXATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FLOW CYTOMETRY; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA; LYMPHOMA CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SCID MOUSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTIFICIAL GENE FUSION; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTARABINE; CYTIDINE DEAMINASE; FEMALE; GENE THERAPY; HUMANS; LYMPHOMA; METHOTREXATE; MICE; MICE, SCID; MUTATION; RETROVIRIDAE; TETRAHYDROFOLATE DEHYDROGENASE; TRANSPLANTATION, HETEROLOGOUS;

ARA;

EID: 4444255952     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.06.115     Document Type: Article

References (50)

1. Rapoport A.P. et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy Bone Marrow Transplant 29 2002 303-312
2. Prince H.M. et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups Br. J. Haematol. 92 1996 880-889
3. Vose J.M. et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease J. Clin. Oncol. 20 2002 2344-2352
4. Faye A. et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children Br. J. Haematol. 115 2001 112-118
5. Maloney D.G. Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches Curr. Opin. Hematol. 6 1999 222-228
6. Stevenson F.K. et al. New strategies for vaccination and immunomodulation in NHL Ann. Hematol. 80 Suppl. 3 2001 B132-B134
7. Fielding A.K. Russell S.J. Gene therapy for B cell lymphomas Cancer Surv. 30 1997 327-342
8. Franken M. et al. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas Nat. Med. 2 1996 1379-1382
9. Krishnan A. et al. Stem cell transplantation and gene therapy for HIV-related lymphomas J. Hematother. Stem Cell Res. 11 2002 765-775
10. Abonour R. et al. Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells Nat. Med. 6 2000 652-658
11. Allay J.A. et al. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells Stem Cells 16 Suppl. 1 1998 223-233
12. Banerjee D. et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase Biochim. Biophys. Acta 1587 2002 164-173
13. Baum C. et al. Gene transfer to augment the therapeutic index of anticancer chemotherapy Gene Ther. 3 1996 1-3
14. 6-alkylguanine-DNA alkyltransferase Gene Ther. 5 1998 842-847
15. Cowan K.H. et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients Clin. Cancer Res. 5 1999 1619-1628
16. Devereux S. et al. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma Gene Ther. 5 1998 403-408
17. Gerson S.L. Drug resistance gene transfer: stem cell protection and therapeutic efficacy Exp. Hematol. 28 2000 1315-1324
18. Hesdorffer C. et al. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation J. Clin. Oncol. 16 1998 165-172
19. Koc O.N. et al. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance Semin. Oncol. 23 1996 46-65
20. Moritz T. Williams D.A. Marrow protection and mdash;transduction of hematopoietic cells with drug resistance genes Cytotherapy 3 2001 67-84
21. Nemunaitis J. Cunningham C. Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors Drug Resist. Update 5 2002 34-46
22. Yanase K. et al. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance Int. J. Cancer 81 1999 134-140
23. James R.I .et al. Transgenic mice expressing the tyr22 variant of murine DHFR: protection of transgenic marrow transplant recipients from lethal doses of methotrexate Exp. Hematol. 25 1997 1286-1295
24. May C. et al. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity Blood 86 1995 2439-2448
25. Williams D.A. et al. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow J. Exp. Med. 166 1987 210-218
26. Zhao S.C. et al. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase Cancer Gene Ther. 1 1994 27-33
27. Isola L.M. Gordon J.W. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene Proc. Natl. Acad. Sci. USA 83 1986 9621-9625
28. James R.I. et al. Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity Blood 96 2000 1334-1341
29. May C. et al. Methotrexate dose-escalation studies in transgenic mice and marrow transplant recipients expressing drug-resistant dihydrofolate reductase activity J. Pharmacol. Exp. Ther. 278 1996 1444-1451
30. Ercikan-Abali E.A. et al. Active site-directed double mutants of dihydrofolate reductase Cancer Res. 56 1996 4142-4145
31. Momparler R.L. et al. Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells Cancer Gene Ther. 3 1996 331-338
32. Sauerbrey A. et al. Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside Hum. Gene Ther. 10 1999 2495-2504
33. Fisher R.I. et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N. Engl. J. Med. 328 1993 1002-1006
34. Khouri I.F. et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma J. Clin. Oncol. 16 1998 3803-3809
35. Plantier-Colcher I. et al. The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma: a prospective study of 71 consecutive cases Leukemia 13 1999 282-288
36. Stamatoullas A. et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma Cancer 77 1996 2302-2307
37. Riviere I. et al. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells Proc. Natl. Acad. Sci. USA 92 1995 6733-6737
38. Sweeney C.L. et al. Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase Cancer Res. 63 2003 1304-1310
39. Zhao S.C. et al. Post-transplant methotrexate administration leads to improved curability of mice bearing a mammary tumor transplanted with marrow transduced with a mutant human dihydrofolate reductase cDNA Hum. Gene Ther. 8 1997 903-909
40. Krall W. Kohn D.B. Expression levels by retroviral vectors based upon the N2 and the MFG backbones Gene Ther. 3 1996 365
41. Adolfsson J. et al. Upregulation of Flt3 expression within the bone marrow Lin( and minus;)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity Immunity 15 2001 659-669
42. Sitnicka E. et al. Key role of flt3 ligand in regulation of the common lymphoid progenitor but not in maintenance of the hematopoietic stem cell pool Immunity 17 2002 463-472
43. Wang L. et al. Effects of the negative control region on expression from retroviral LTR Mol. Ther. 7 2003 438-440
44. Vaishampayan U. et al. Outcome of relapsed non-Hodgkin's lymphoma patients after allogeneic and autologous transplantation Cancer Invest. 20 2002 303-310
45. Sorrentino B.P. et al. In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors Prog. Exp. Tumor Res. 36 1999 143-161
46. Warlick C.A. et al. In vivo selection of antifolate-resistant transgenic hematopoietic stem cells in a murine bone marrow transplant model J. Pharmacol. Exp. Ther. 300 2002 50-56
47. Bhalla K. et al. Effects of thymidine and hydroxyurea on the metabolism and cytotoxicity of 1-B-D arabinofuranosylcytosine in highly resistant human leukemia cells Blood 78 1991 2937-2944
48. Danhauser L.L. Rustum Y.M. Potential for selective enhancement of the in vivo metabolism of 1- and β-D-arabinofuranosylcytosine in rats by thymidine pretreatment Cancer Res. 45 1985 2002-2007
49. Capiaux G.M. et al. Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil Hum. Gene Ther. 14 2003 435-446
50. Goy A. et al. Establishment of a human cell line (SKI-DLCL-1) with a t(1;14) (q21;q32) translocation from the ascites of a patient with diffuse large cell lymphoma Leuk. Lymphoma 40 2001 419-423